What can we learn from the edaravone development program for ALS?

Abstract

Edaravone’s development into an ALS therapeutic has been a process which began with preclinical studies regarding its potential in targeting ALS. Despite edaravone’s inability to show benefit in a general ALS population, an important post-hoc analysis showed that a clinical subset of patients had benefit. Most importantly, a subsequent study examining the capacity of edaravone to have benefit in this specific subset of ALS patients was successful in meeting its primary outcome measures. Questions regarding whether the dosing regimen could be simplified or improved, the duration of the effects, and the timing of the potential treatment to different stages of disease remain to be answered. However, the benefit of this compound in delivering a meaningful therapy to ALS patients and the lessons learned with regard to its development should widen interest in clinical research so that additional strategies for treating ALS may become available to patients.

Keywords:

• Therapy
• drug
• clinical trial
• motor neuron disease

Declaration of interest

Scientific Advisory Board of Q Therapeutics, Inc., Scientific Advisory Board, Above and Beyond NB, LLC. Consultant to: Cytokinetics, Inc., Biohaven Pharmaceuticals.

Open access publication of this article was funded by Mitsubishi Tanabe Pharma America, Inc.